Aggressive Non-Hodgkin Lymphoma

Known as: Aggressive Non-Hodgkin's Lymphoma, Non-Hodgkin lymphoma, aggressive, NOS, aggressive lymphoma 
A non-Hodgkin lymphoma with an aggressive clinical course. Representative examples include Burkitt lymphoma, mantle cell lymphoma, and… (More)
National Institutes of Health

Related topics

Related topics

11 relations
Atypical lymphocyteHematopoietic and Lymphoid CellHematopoietic and Lymphoid TissueLymphatic System
(More)

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 -- the Southwest Oncology Group.
PURPOSE To investigate the incidence, natural history, and risk factors predictive of CNS relapse in patients with de novo… (More)
Is this relevant?
Highly Cited
2008
Highly Cited
2008
Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
PURPOSE The major cause of death in aggressive lymphoma is relapse or nonresponse to initial therapy. Lenalidomide has activity… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma.
BACKGROUND Chemoradiotherapy is standard treatment for localized aggressive lymphoma. To determine the optimal therapy for… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.
Assessment of early therapeutic response using metabolic imaging is potentially useful to determine prognosis in aggressive… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group study 1484.
PURPOSE To compare low-dose (30 Gy) radiotherapy (RT) with observation (OBS) in limited-stage aggressive lymphoma patients… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
Cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21), is standard chemotherapy for… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL…
The combination of cyclophosphamide, doxorubicin, vincristine, and prednisone, given every 3 weeks (CHOP-21) is standard… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma.
We conducted a randomized trial to compare the intensive conventional chemotherapy regimen ACVBP (doxorubicin, cyclophosphamide… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
2003
2003
Early therapy monitoring with FDG-PET in aggressive non-Hodgkin’s lymphoma and Hodgkin’s lymphoma
This study was designed to determine the value of 2-[fluorine-18]-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2002
Highly Cited
2002
PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin's disease.
UNLABELLED Early identification of chemotherapy-refractory lymphoma patients provides a basis for alternative treatment… (More)
Is this relevant?